SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY FLASH L impact

Novartis's Multiple Sclerosis Trial Results Match Best Hopes — Market Talk

Novartis's trial results for a multiple sclerosis drug are in line with a blue-sky scenario, UBS analysts say in a research note. The Swiss drugmaker's results from two late-stage studies point to a greater reduction in annualized relapse rates with its Rhapsido compared to Sanofi's Aubagio, with n…

NOT

This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.

Related stories